Chugai and Galderma Announce Global License Agreement for Nemolizumab (CIM331), Novel Biologic for Skin Diseases
Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) and Galderma Pharma S.A. today announced that they have entered into a global license agreement for “nemolizumab” (CIM331) the anti-IL-31 receptor A humanized monoclonal antibody created by Chugai, which is currently under development for atopic dermatitis and pruritus in hemodialysis patients.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160720005582/en/
“This agreement highlights the great expectation for nemolizumab which
possesses a novel mechanism of action to improve atopic dermatitis by
breaking the itch-scratch cycle,” said Chugai’s Representative Director,
President and Chief Operating Officer, Tatsuro Kosaka. “Along with
Galderma, we are committed to the development of nemolizumab to bring
this innovative drug to patients with atopic dermatitis worldwide.”
“Our vision is to provide a new medicine to patients suffering from many diseases with itch as the main symptom. This agreement is a great step forward towards the realization of this vision,” said Dr. Athos Gianella-Borradori, Chief Medical Officer of Chugai Pharma USA, Inc. “This partnership with Galderma will ensure that the full potential of nemolizumab will be realized.“
“This new strategic agreement marks another important step in our journey to meet the needs of patients and healthcare professionals all around the world by delivering breakthrough innovative medical solutions along the entire spectrum of technological options” said Stuart Raetzman, Chief Executive Officer of Galderma Pharma S.A. “Nemolizumab is a new innovative biotherapy candidate which will be developed as a clearly differentiated first in class solution for patients with moderate-to-severe atopic dermatitis”, added Dr. Thibaud Portal, Vice-President of Galderma’s Prescription Business. “This first foray for Galderma in the field of biotherapies will be truly transformational for our prescription business and illustrates our ambitions to fulfill all the needs of our patients, from diagnosis to treatment, maintenance and prevention.”
Nemolizumab was discovered by Chugai, and uses Chugai’s proprietary antibody engineering technology ACT-Ig, which can extend the biological half-life of antibodies in blood. IL-31 has been identified as a pruritogenic cytokine,1 and reported to be associated with pruritus in many diseases including atopic dermatitis and hemodialysis.2,3 Nemolizumab is designed to inhibit the activities of IL-31 by competitively blocking binding with its receptor. Chugai has obtained positive results in a global phase ll study in patients with moderate-to-severe atopic dermatitis in five countries in US, Europe and Japan. Currently, a phase ll study for pruritus in hemodialysis patients is ongoing in Japan.
Under the agreement, Chugai will grant Galderma an exclusive license for the development and marketing of nemolizumab worldwide, with the exception of Japan and Taiwan. Chugai will continue to be responsible for product manufacturing and supply of nemolizumab. Under the terms of the agreement, Chugai will receive an upfront, milestone and royalty payments from Galderma.
This transaction is subject to potential competition authority clearances and other customary closing conditions.
About Atopic Dermatitis
Atopic dermatitis (AD) is a complex multi-factorial disease combining two types of anomalies: alteration of the epidermal barrier and sensibility to allergens. It is a chronic, pruriginous, inflammatory dermatitis manifesting itself under the form of flares. It is the most common dermatitis among children but can subsist at any age: patient types vary widely and range from infants to seniors, acute to chronic, and mild to severe. It is caused by genetic and environmental factors: new discoveries are elucidating the pathogenic pathways that drive AD.
About itch-scratch cycle
Skin itchiness causes scratch, which enhances inflammation and further aggregation of itchiness. This vicious cycle called the itch-scratch cycle is known as an exacerbating factor for dermatitis.
Chugai Pharmaceutical is one of Japan’s leading research-based
pharmaceutical companies with strengths in biotechnology products.
Chugai, based in Tokyo, specializes in prescription pharmaceuticals and
is listed on the 1st section of the Tokyo Stock Exchange. As an
important member of the Roche Group, Chugai is actively involved in R&D
activities in Japan and abroad. Specifically, Chugai is working to
develop innovative products which may satisfy the unmet medical needs,
mainly focusing on the oncology area.
In Japan, Chugai’s research facilities in Gotemba and Kamakura are collaborating to develop new pharmaceuticals and laboratories in Ukima are conducting research for technology development for industrial production. Overseas, Chugai Pharmabody Research based in Singapore is engaged in research focusing on the generation of novel antibody drugs by utilizing Chugai’s proprietary innovative antibody engineering technologies. Chugai Pharma USA and Chugai Pharma Europe are engaged in clinical development activities in the United States and Europe.
The consolidated revenue in 2015 of Chugai totalled 498.8 billion yen and the operating income was 90.7 billion yen (IFRS Core basis).
Additional information is available on the internet at http://www.chugai-pharm.co.jp/english.
Dating back to 1981, Galderma is now present in 100 countries with an
extensive product portfolio to treat a range of dermatological
conditions. The company partners with health care professionals around
the world to meet the skin health needs of people throughout their
lifetime. Galderma is a leader in research and development of
scientifically-defined and medically-proven solutions for the skin, hair
For more information, please visit http://www.galderma.com/.
|1.||Dillon SR, Sprecher C, Hammond A, Bilsborough J, Rosenfeld-Franklin M, Presnell SR, Haugen HS, Maurer M, Harder B, Johnston J, Bort S, Mudri S, Kuijper JL, Bukowski T, Shea P, Dong DL, Dasovich M, Grant FJ, Lockwood L, Levin SD, LeCiel C, Waggie K, Day H, Topouzis S, Kramer J, Kuestner R, Chen Z, Foster D, Parrish-Novak J, Gross JA. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat Immunol 2004;5:752-60.|
|2.||Sonkoly E, Muller A, Lauerma AI, Pivarcsi A, Soto H, Kemeny L, Alenius H, Cieu-Nosjean MC, Meller S, Ricker J, Steinhoff M, Hoffmann TK, Ruzicka T, Zlotnik A, Homey B. IL-31: a new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol 2006;117:411-7.|
|3.||Ko MJ, Peng YS, Chen HY, Hsu SP, Pai MF, Yang JY, et al. Interleukin-31 is associated with uremic pruritus in patients receiving hemodialysis. J Am Acad Dermatol 2014;71:1151-9.|
Global Vice President Communications
Chugai Pharmaceutical Co., Ltd.
Media Relations Group, Corporate Communications Dept.,
For US media
Chugai Pharma USA Inc.
For European media
Chugai Pharma France SAS
For Taiwanese media
Chugai Pharma Taiwan Ltd.
Susan Chou, Osamu Kagawa
Chugai Pharmaceutical Co., Ltd.
Investor Relations Group, Corporate Communications Dept.,
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Orange Acquires Basefarm Holding and Becomes a European Leader in Cloud Computing Services for the Enterprise Sector16.7.2018 07:22 | Pressemelding
Following a competitive tender process initiated by Abry Partners for its stake in Basefarm, the Orange Group, through its enterprise subsidiary Orange Business Services, has announced today the signature of a contract to acquire 100% of the company’s capital for an enterprise value of 350 million euros. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180716005214/en/ Basefarm is a leading European player in cloud-based infrastructure and services, as well as the management of critical applications and data analysis. The company, which recorded revenues of over 100 million euros in 2017, has enjoyed strong growth since 2015. Basefarm has a strong operational presence in several European countries, particularly in Norway, Sweden, the Netherlands, Austria and in Germany, where it boasts a cutting-edge big data activity. Its business proposition lies at the forefront of the most innovative services in cloud computing, Big Data a
Spirit AeroSystems and Norsk Titanium Announce Start of Production Qualification for Commercial Aircraft Parts16.7.2018 07:00 | Pressemelding
Spirit AeroSystems [NYSE: SPR] and Norsk Titanium US Inc. (NTi), have reached an agreement to initiate qualification of Spirit’s first additive-manufactured, titanium, structural component for the Boeing 787. This qualification will validate NTi’s production and industrialization processes, integrate Spirit’s workscope of machining final parts from additively manufactured near-net shapes and verify material and final part conformity to requirements. “Spirit has had a comprehensive and long relationship with Norsk Titanium, and this part will be our first additive structural titanium component incorporated into a commercial airplane program,” said Spirit AeroSystems Senior Vice President of Fabrication and Supply Chain Management, Ron Rabe. NTi is the world’s first FAA-approved, OEM qualified, supplier of additive-manufactured, structural titanium components. NTi’s proprietary Rapid Plasma Deposition™ (RPD™) process has been in serial production of Boeing 787 titanium components since A
New Study Investigates the Utility of Masimo PVi® as Part of Goal-Directed Fluid Management in Patients Undergoing Colorectal Surgery16.7.2018 05:00 | Pressemelding
Masimo (NASDAQ: MASI) announced today the findings of a recently published study in which researchers at Kocaeli University in Turkey compared the performance of conventional fluid management (CFM) to goal-directed fluid management (GDFM) using Masimo PVi® (pleth variability index, measured noninvasively and continuously using SET® pulse oximetry sensors) in patients undergoing elective colorectal surgery. The primary points of comparison were the amount of crystalloids administered and blood lactate and serum creatinine levels during the intraoperative period.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180715005048/en/ Masimo Radical-7® with PVi®, SpHb®, and RD rainbow SET™ Sensor (Photo: Business Wire) In the study, Dr. Cesur and colleagues, noting the importance of intraoperative fluid management in terms of postoperative organ perfusion and complications, sought to compare the effects of CFM (guided by clinical asse
Alipay and Singapore Tourism Board join hands to boost Chinese tourist spending16.7.2018 02:00 | Pressemelding
Alipay, the world’s leading mobile and online payment and lifestyle platform operated by Ant Financial Services Group, together with the Singapore Tourism Board (STB), have launched a series of joint marketing initiatives aimed at raising destination awareness of Singapore and driving tourist spending among Chinese visitors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180715005021/en/ Alipay and STB signed a Memorandum of Understanding (MOU) in September 2017 to enhance Chinese tourists’ overall experience in Singapore. Under the MOU, both parties agreed, among other things, to explore co-investing in joint-marketing initiatives to encourage Chinese tourists to spend with Alipay while in Singapore. Since signing the MOU, Alipay has experienced double-digit growth in user spending. China has also become Singapore’s top market in 2017 for both tourism receipts and visitor arrivals, contributing S$4.2 billion in tourism rece
Koza Altin Welcomes Court’s Rejection of Akin Ipek’s Share Purchase Agreement13.7.2018 15:58 | Pressemelding
A Turkish Court has found against businessman Akin Ipek this week – ruling that a share purchase agreement, which he had submitted as vital evidence in support of his case against the Turkish state, is null and void. The matter was brought to the Ankara Commercial Court in March 2017 by Koza Holding (parent company of Koza Altin) which, according to Mr Ipek’s share purchase agreement, purportedly transferred all of its shares to Ipek Investment Limited. Koza Holding filed the lawsuit for legal recognition that the share purchase agreement is void. The ruling in Turkey follows on from an earlier judgment set down by the English High Court, which rejected Mr Ipek’s attempt to use up to £3m of UK subsidiary Koza Ltd’s money to fund a claim against the Turkish State at the International Centre for Settlement of Investment Disputes (ICSID). In the English ruling, Deputy Judge Richard Spearman QC declared the “authenticity” of the share purchase agreement as “open to very serious doubt”. The
Mindbreeze Positioned in the Leaders Quadrant of the Gartner’s 2018 Magic Quadrant for Insight Engines13.7.2018 15:27 | Pressemelding
Mindbreeze, a leading global provider of appliances and cloud services for information insight and applied artificial intelligence with a focus on knowledge management for leading international companies, announced today that Gartner, Inc. has positioned Mindbreeze in the Leaders quadrant of the 2018 Magic Quadrant for Insight Engines. Mindbreeze is positioned highest on the ability to execute axis. The research and advisory firm Gartner, Inc. evaluated 13 different providers from all over the world. “Understanding the meaning of information is a key priority for today’s customers. Mindbreeze InSpire leverages the full power of our sophisticated AI engine to provide actionable insights and answers ̶ not just more data. Seeing our position in the Magic Quadrant, my first reaction was ‘AWESOME’. Insight Engine was positioned the highest on the ability to execute axis and we believe that's exactly what sets us apart from our competitors. We made the bold move to focus on product innovatio